

Anticoagulants and antiplatelets	
Apixaban	[1, 2]
Bivalirudin	[3]
Clopidogrel	[1, 4]
Dabigatran	[1, 5]
Dipyridamole	[6]
Enoxaparin	[1, 2]
Fondaparinux	[1, 7]
Prasugrel	[8]
Rivaroxaban	[9]
Vorapaxar	[10]
Mucoactive agents	
Ambroxol	[11]
Bromhexine	[1, 12]
Guaifenesin	[1, 13]
Acetylcysteine	[14]
Bronchodilator agents	
Ensifentrine	[15]
Formoterol	[1, 16]
Glycopyrronium	[1]
Indacaterol	[1]
Ipratropium	[1]
Levalbuterol	[1]
Metaproterenol	[1, 17]
Pirbuterol	[1]
Salbutamol	[1, 18]
Salmeterol	[1, 19]
Terbutaline	[1]
Theophylline	[1, 20]
Tiotropium	[1, 21]
Umeclidinium	[1]
Vilanterol	[1]
Antihypoxic agents	
Almitrine	[22]
Triiodothyronine	[23]
Desidustat	[24]
Razuprotafib	[25]
Vadadustat	[26]
Angiotensin II receptor blockers	
Candesartan	[27]
Irbesartan	[28]
Losartan	[29]
Telmisartan	[30]
Valsartan	[31]
Antimicrobial agents	
Amodiaquine	[1, 32]

Amoxicillin	[1, 33]
Ampicillin	[1, 33]
Artemisinin	[34]
Atovaquone	[35]
Azithromycin	[36]
Benzylpenicillin	[37]
Biltricide	[37]
Cefaclor	[1, 38]
Cefamandole	[39]
Cefditoren Pivoxil	[40]
Cefotaxime	[1, 41]
Ceftriaxone	[1, 18]
Cefuroxime	[1, 42]
Chloramphenicol	[43]
Chloroquine	[44]
Ciprofloxacin	[1, 45]
Clarithromycin	[1, 46]
Clindamycin	[1]
Clioquinol	[47]
Doxycycline	[48]
Erythromycin	[1, 49]
Fusidic acid	[1]
Gatifloxacin	[1, 50]
Gemifloxacin	[1]
Hydroxychloroquine	[51]
Ivermectin	[52]
Levamisole	[53]
Levofloxacin	[45]
Linezolid	[1]
Lumefantrine	[1, 54]
Mefloquine	[1, 54]
Metronidazole	[55]
Moxifloxacin	[1, 45]
Niclosamide	[56]
Nitazoxanide	[57]
Norfloxacin	[1]
Ofloxacin	[1]
Oxolinic acid	[58]
Piperaquine	[1, 34]
Polymyxin B1	[59]
Proguanil	[1, 60]
Pyrazinamide	[1]
Pyrimethamine	[1]
Pyronaridine	[61]
Quinacrine	[61]
Quinine	[1, 62]
Rapamycin	[63]

Roxithromycin	[1]
Sulfamethoxazole	[64]
Tafenoquine	[65]
Terbinafine	[37]
Tizoxanide	[66]
Trimethoprim	[64]
Immunomodulatory agents	
Abivertinib	[67]
ABX464	[68]
Acalabrutinib	[69]
Acebilustat	[70]
Acetylsalicylic acid	[71]
Adenosine	[72]
Alvelestat	[73]
Anakinra	[74]
ANG-3777	[75]
Apremilast	[76]
AT-001	[77]
ATI-450	[78]
Atorvastatin	[79]
ATR-002	[80]
Avasopasem	[81]
AZD1656	[82]
Baricitinib	[83]
Beclomethasone	[1]
BGE-175	[84]
Brensocatib	[85]
Brexanolone	[86]
Budesonide	[1, 87]
Bucillamine	[88]
Carvedilol	[89]
Celecoxib	[90]
Cenicriviroc	[91]
Chlorpromazine	[92]
Ciclesonide	[1, 93]
CM4620	[94]
Cromoglycate	[1, 95]
Cyclosporine	[96]
Dapagliflozin	[97]
Dapanustrile	[98]
Dexamethasone	[99]
Dexmedetomidine	[100]
DFV890	[101]
Duvelisib	[102]
Ebastine	[103]
EC-18	[104]
Edaravone	[105]

Eplerenone	[28]
Equilin	[28]
Escitalopram	[106]
Famotidine	[107]
Fenretinide	[108]
Fingolimod	[109]
Fluoxetine	[106]
Fluticasone	[1, 110]
Fluvoxamine	[111]
Fostamatinib	[112]
FP-025	[113]
Furosemide	[114]
Hydrocortisone	[115]
Ibrutinib	[116]
Ibudilast	[117]
Ifenprodil	[118]
Imatinib	[119]
Imiquimod	[120]
Indomethacin	[121]
Jaktinib hydrochloride	[122]
Lidocaine	[123]
Losmapimod	[124]
M5049	[125]
Maraviroc	[126]
Melatonin	[127]
Mesalazine	[128]
Metformin	[129]
Methylprednisolone	[115]
Mirtazapine	[106]
Montelukast	[130]
NA-831	[131]
Naltrexone	[132]
Naproxen	[133]
Nintedanib	[134]
Noscapine	[135]
Opaganib	[136]
Oxymetholone	[137]
Oxypurinol	[138]
Ozanimod	[139]
Pacritinib	[140]
Paroxetine	[106]
Pentoxifylline	[141]
PF-06650833	[142]
Piclidenoson	[143]
Prednisolone	[1, 144]
Ramelteon	[145]
Regadenoson	[86]

Reparixin	[146]
Roflumilast	[1]
Rosuvastatin	[147]
Ruxolitinib	[148]
RTB101	[149]
Silmitasertib	[150]
Sirolimus	[151]
Tacrolimus	[152]
TD-0903	[153]
Tempol	[154]
Thalidomide	[155]
Tofacitinib	[156]
Tradipitant	[157]
Tramadol	[158]
Tranilast	[159]
Ulinastatin	[160]
VB-201	[161]
Venlafaxine	[106]
VGX-1027	[162]
Zavegepant	[163]
Binding and internalisation inhibitors	
7-hydroxystaurosporine	[164]
Acidinium	[165]
Afeletcan	[165]
Alprostadil	[165]
Amcinonide	[165]
Amiodarone	[166]
Apilimod (LAM-002A)	[167]
Aprepitant	[165]
Atropine	[165]
Azathioprine	[165]
AZD-8330	[165]
Azilsartan	[165]
Bafetinib	[164]
Barusiban	[165]
Bekanamycin	[165]
Bemcentinib	[168]
Bendamustine	[165]
Berzosertib	[165]
Bicalutamide	[169, 170]
Birinapant	[165]
BLD-2660	[171]
Brigatinib	[165]
Brilacidin	[172]
Bromocriptine	[165]
Brompheniramine	[165]

Bunazosin	[165]
Calcifediol	[165]
Camostat	[173, 174]
Captopril	[165]
Cefixime	[165]
Ceritinib	[165]
Cimicoxib	[165]
Clobazam	[165]
Cobimetinib	[165]
Conivaptan	[165]
Copanlisib	[165]
CP-195543	[165]
Dacomitinib	[165]
Dasatinib	[165]
Decanoyl-RVKR-chloromethylketone (CMK)	[175]
Deferasirox	[165]
Delavirdine	[165]
Desvenlafaxine	[165]
Deutivacaftor	[165]
Dihydroergotamine	[165]
Diminazene	[176]
Disopyramide	[165]
Doxazosin	[165]
Dutasteride	[169]
Elamipretide	[165]
Eletriptan	[165]
Entrectinib	[177]
Enzalutamide	[178]
Fenofibrate	[179]
Fluvastatin	[165]
Gentamicin	[165]
Iloprost	[165]
Ipamorelin	[165]
Isocarboxazid	[165]
Kanamycin	[165]
Ketoconazole	[165]
Lapatinib	[165]
Levomefolate	[165]
Lixivaptan	[165]
Lometrexol	[165]
Lomibuvir	[165]
Lumacaftor	[180]
MDL-28170	[181]
Megestrol acetate	[165]
Methsuximide	[165]
Methylnaltrexone	[165]

MG-132	[182]
MI-1851	[183]
MI-1900	[183]
MI-432	[183]
Midazolam	[165]
Modithromycin	[165]
Nafamostat	[184, 185]
Nafithromycin	[165]
Naloxone	[165]
Naphthofluorescein	[175]
Nebivolol	[165]
Netilmicin	[165]
Netupitant	[165]
Nilotinib	[177]
Nilutamide	[165]
Nimesulide	[186]
Omeprazole	[187]
ONO 5334	[181]
Orphenadrine	[165]
Otamixaban	[188]
Panobinostat	[165]
Pelitinib	[165]
Pelitrexol	[165]
Perphenazine	[165]
Pimecrolimus	[165]
Pioglitazone	[165]
Pramoxine	[165]
Prazosin	[165]
Primaquine	[165]
Prochlorperazine	[165]
Propylhexedrine	[165]
Proxalutamide	[189]
Rabeprazole	[165]
Raltitrexed	[165]
Rebamipide	[165]
Recoflavone	[165]
Ruzasvir	[165]
Sivifene	[165]
Sonidegib	[165]
Spirolactone	[190]
Tadalafil	[165]
Terazosin	[165]
Tetrahydroquinoline oxocarbazate	[191]
Ticlopidine	[165]
Tivozanib	[165]
Treprostinil	[165]
Triazolam	[165]

Umifenovir (Arbidol)	[192]
Vadimezan	[165]
VBY-825	[181]
Zileuton	[165]
Ziritaxestat	[165]
Classical and potential antivirals	
5h	[193]
6-mercaptopurine	[194]
6-thioguanine	[194]
Abacavir	[1, 195]
Acyclovir	[1, 196]
Adefovir	[1, 197]
a-ketoamide 13b	[198]
a-ketoamide-11r	[198]
Alisporivir	[199]
Amantadine	[1, 200]
Amitriptyline	[37, 201]
Amoxapine	[202]
Argiprestocin	[59]
ASC09	[203]
Asunaprevir	[204]
AT-527	[205, 206]
Atazanavir	[207]
Atosiban	[59]
Azelastine	[208]
Azvudine	[209]
B02	[210]
Baloxavir marboxil	[211, 212]
Bardoxolone methyl	[213]
BAY-2402234	[214]
Benzydamine	[202]
Bepidil	[202, 215]
Bictegravir	[216]
Boceprevir	[217]
Brequinar	[218]
Brivudine	[204, 219]
Carbetocin	[59]
Carmofur	[220]
Celgosivir	[221]
Chlormadinone acetate	[202]
Chlorothiazide	[37]
Chlorphenesin carbamate	[43]
Chlorprothixene	[202]
Cidofovir	[204]
Cinacalcet	[37]
Cisatracurium	[59]

Cistinexine	[59]
Clemastine	[202]
Clevudine	[222]
Clofazimine	[181]
Clomipramine	[202]
Cobicistat	[223]
CPI-169	[224]
Cyclobenzaprine	[202]
Cyproheptadine	[202]
Daclatasvir	[225]
Danoprevir	[226]
Darunavir	[223]
Dasabuvir	[204]
Decitabine	[227]
Demoxytocin	[59]
Didanosine	[204]
Difeterol	[202]
Dimethisoquin	[202]
Diphenhydramine	[208]
Disulfiram	[228]
Ditercalinium	[59]
Docosanol	[204]
Dolutegravir	[1]
Doravirine	[204]
Duloxetine	[202]
Ebiratide	[59]
Ebselen	[229]
Efavirenz	[204]
Elbasvir	[204]
Elvitegravir	[1]
Emtricitabine	[230]
Enisamium	[231]
Ensitrelvir	[232]
Entecavir	[1]
Ethoheptazine	[37]
Ethopropazine	[202]
Etravirine	[204, 233]
Everolimus	[234]
Examorelin	[59]
Famciclovir	[1]
Favipiravir	[235]
Favipiravir ribofuranosyl-5'-triphosphate	[235]
Fluphenazine	[202]
Fosamprenavir	[1, 236]
Foscarnet	[204]
Galidesivir	[237]

Ganciclovir	[1, 238]
GC376	[217]
Glecaprevir	[126]
GNS561	[239]
Grazoprevir	[240, 241]
GRL0617	[242]
GRL-1720	[193]
Homochlorcyclizine	[202]
Hydroxyzine	[208]
Idoxuridine	[204]
Imipramine	[202]
IMU-838	[243]
Indinavir	[1]
Labetalol	[204]
Lamivudine	[1]
Laninamivir octanoate	[244]
Lanreotide	[59]
Ledipasvir	[245]
Leflunomide	[246]
Letermovir	[204]
Levodropropizine	[43]
Lopinavir	[247]
Loxapine	[202]
Lynestrenol	[202]
Lypressin	[59]
Maprotiline	[202]
Masitinib	[248]
Merimepodib	[249]
Molnupiravir	[250]
Nacartocin	[59]
Naphazoline	[37]
Narlaprevir	[251]
Nelfinavir	[252]
Nevirapine	[204]
Nylidrin	[202]
Ombitasvir	[204]
Ornipressin	[59]
Oseltamivir	[253]
Paritaprevir	[204]
Penciclovir	[1]
Peramivir	[204]
Pethidine	[37]
PF-00835231	[254]
PF-07304814	[255]
PF-07321332	[256]
Pibrentasvir	[126]
Pizotifen	[202]

Podofilox	[257]
Procainamide	[37]
Promazine	[202]
Promethazine	[202]
PTC299	[258]
PX-12	[259]
Pyrazofurin	[214]
Raltegravir	[1]
Remdesivir	[260]
Remdesivir triphosphate	[260]
Ribavirin	[261]
Ribavirin 5'-monophosphate	[261]
Rilapladib	[58]
Rimantadine	[1]
Ritonavir	[247]
S312	[262]
S416	[262]
Saquinavir	[1]
Selinexor	[263]
Simeprevir	[264]
Sinefungin	[265]
Sofosbuvir	[225]
Spiperone	[202]
Stavudine	[204]
Suramin	[266]
Tamoxifen	[202]
Telaprevir	[204]
Telbivudine	[1]
Temsirolimus	[234]
Tenofovir alafenamide	[204, 267]
Tenofovir disoproxil	[204, 267]
Tetrahydrozoline	[37]
Thymidine	[43]
Tideglusib	[259]
Tigecycline	[43]
Tilorone	[61]
Tipranavir	[1]
Tolterodine	[202]
Toremifene	[268]
Triazavirin - <u>riamilovir</u>	[269]
Triflupromazine	[202]
Trifluridine	[204]
Trimipramine	[202]
Triparanol	[202]
Tripeleennamine	[202]
Valacyclovir	[1]
Valganciclovir	[1]

Vaniprevir	[204]
Velpatasvir	[204]
Vidarabine	[204]
VIR250	[270]
VIR251	[270]
Voxilaprevir	[204]
XC221	[271]
XR8-23	[272]
XR8-24	[272]
XR8-65	[272]
XR8-69	[272]
XR8-83	[272]
Z LVG CHN2	[181]
Zalcitabine	[1]
Zanamivir	[204]
Zidovudine	[1]
Zotatifin	[273]
Zotepine	[202]
Natural compounds	
(+)-7,7-Bis[(5R,7R,9R,10S)-2-Oxocadinan-3,6(11)-Dien-12,7-Olide]	[274]
(+)-Oxoturkiyenine	[275]
(2S)-Eriodictyol-7-O-(6"-O-galloyl)-beta-D-glucopyranoside	[276]
1,3,4,6-tetra-O-galloyl-β-d-glucose	[277]
18-Hydroxy-3-epi-alpha-yohimbine	[278]
2-(3,4-dihydroxyphenyl)-2-[[2-(3,4-dihydroxyphenyl)-3,4-dihydro-5,7-dihydroxy-2H-1-benzopyran-3-yl]oxy]-3,4-dihydro-2H-1-benzopyran-3,4,5,7-tetrol) - Procyanidin	[43]
2-Hydroxy-3-methoxystrychnine	[275]
3,5,7,3',4',5'-hexahydroxyflavone-3-O-beta-D-glucopyranoside	[276]
3Alpha,17Alpha-Cinchophylline	[275]
4-(3,4-Dihydroxyphenyl)-7-methoxy-5-[(6-O-β-D-xylopyranosyl)-β-D-glucopyranosyl]oxy]-2H-1-benzopyran-2-one	[279]
4-hydroxyisolonchocarpin	[280]
4'-O-methylbavachalcone	[280]
5,7,3',4'-Tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone	[276]
5-amino levulinic acid	[281]
7-Deacetyl-7-benzoylgedunin	[282]

Acteoside	[283]
Adlumidine	[275]
Alantolactone	[284]
Allicin	[285]
Alloyohimbine	[278]
alpha-Colubrine	[275]
Amaranthin	[276]
Amarogentin	[286]
Amentoflavone	[280]
Anabsinthin	[287]
Anaferine	[288]
Andrographolide	[289]
Anisotine	[286]
Anthraquinone	[290]
Antroquinonol	[291]
Apigenin	[292]
Ararobinol	[275]
Arctigenin	[293]
Arjunic acid	[294]
Asparagine A	[278]
Baicalein	[295]
Baicalin	[295]
Bavachin	[284]
Benzquercin	[59]
Berberine	[296]
Betulinic acid	[297]
Biflavone	[280]
Bisdemethoxycurcumin	[298]
Brousochalcone A	[280]
Bruceine A	[284]
Brusatol	[284]
Bufalin	[284]
Bufotaline	[284]
Cadambine	[299]
Caffeic acid phenethyl ester - Propolis (from bees)	[300]
Calceolarioside B	[276]
Calendoflaside	[301]
Camphor	[302]
Camptothecin	[287]
Cannabidiol	[303]
Cannabigerol	[303]
Carvacrol	[304]
Castalagin	[305]
Catechin	[306]
Cepharanthine	[284]
Chebulagic acid	[307]

Cholecalciferol	[308]
Chrysin	[300]
Cinobufagin	[284]
Clemastanin B	[309]
Colchicine	[310]
Colistin	[276]
Coniferyl aldehyde	[284]
Cordifolioside A	[311]
Corilagin	[312]
Cornuside	[284]
Corosolic acid	[282]
Crocetin	[313]
Cryptotanshinone	[284]
Curcumin	[314]
Cyanidin-3-O-glucoside	[315]
Cyclocurcumin	[289]
Dehydrocostus lactone	[284]
Dehydrodiisoeugenol	[284]
Demethoxycurcumin	[298]
Digoxin	[284]
Edgeworoside C	[275]
Egenine	[275]
Eicosapentaenoic acid	[316]
Ellagic acid	[294]
Ellipticine	[287]
Emetine	[317]
Emodin	[290]
Epicatechin gallate	[306]
Epigallocatechin	[306]
Epigallocatechin gallate	[306]
Epsilon-viniferin	[318]
Euscaphic acid	[294]
Fangchinoline	[284]
Fisetin	[319]
Folic acid	[320]
Friedelin	[321]
Galangin	[300]
Gallocatechin gallate	[280]
Geraniin	[322]
Gingerol	[297]
Glabridin	[323]
Glucogallin	[324]
Glycyrrhizic acid	[282]
Gmelanone	[318]
Grandinin	[305]
Gummadiol	[278]
Hesperidin	[325]

Hesperitin	[300]
Homoharringtonine	[326]
Hypericin	[315]
Icariin	[327]
Igesterin	[280]
Isoalantolactone	[284]
Isobavachalcone	[284]
Isoliensinine	[284]
Isoquercetin	[328]
Isorhamnetin-3-O- β -D-glucoside	[301]
Isorientin 4'-O-glucoside 2''-O- <i>p</i> -hydroxybenzoate	[329]
Jasmonic acid	[330]
Kaempferitrin	[331]
Kaempferol	[300]
Kaempferol 3-O- β -rutinoside	[279]
Kazinol-A	[280]
Licoleafol	[276]
Liensinine	[284]
Limonin	[300]
Limonin glucoside	[282]
Lupinifolin	[327]
Luteolin	[280]
Luteolin-7-glucoside	[297]
Lycorine	[284]
Magnoflorine	[311]
Mangiferin	[324]
Maslinic acid	[282]
Matrine	[332]
Methyl rosmarinate	[276]
Momordin Ic	[284]
Myricetin	[300]
Myricetin-3-O- β -D-glucopyran oside	[276]
Myricitrin	[276]
Naringenin	[297]
Naringin	[327]
Neohesperidin	[327]
Nicotinamide riboside	[333]
Nimbocinol	[334]
Niranthin	[335]
Nordihydroguaiaretic acid	[336, 337]
Obacunone	[282]
Oleuropein	[338]
Oridonin	[284, 339]
Papyriflavonol A	[280]
Patentiflorin B	[340]
Peimisine	[318]

Peonidin 3-O-glucoside	[279]
Periplocoside	[284]
Phaitanthrin D	[43]
Phlorizin	[324]
Phycocyanobilin	[320]
Phycoerythrobilin	[320]
Phycourobilin ((4S, 10Z, 16R)-phycourobilin)	[320]
Picrasidine M	[275]
Pinocembrin	[300]
Piperine	[314]
Piperolactam A	[287]
Platycodin D	[43]
Proanthocyanidin B2	[299]
Prulifloxacin	[276]
Pseudo-alpha-Colubrine	[275]
Pseudohypericin	[341]
Psoralidin	[280]
Punicalagin	[307]
Putaminoxin B	[330]
Putaminoxin D	[330]
Qingdainone	[275]
Quercetagenin	[342, 343]
Quercetin	[344]
Quercetin 3-O- α -L-arabinopyranoside	[279]
Quercetin-3-D-xyloside	[279]
Quercitrin	[327]
Reserpine	[284]
Resveratrol	[121]
Rhamnazin-3-O-rutinoside	[280]
Rhein	[290]
Roburic acid	[284]
Rugosanine B	[275]
Rutin	[315]
Savinin	[280]
Scutellarin	[297]
Shikonin	[259]
Silibinin A	[345]
Silibinin B	[345]
Silymonin	[275]
Solanine	[283]
Somniferine	[329]
Speciophylline	[299]
Stigmasterol	[321]
Strychnine N-oxide	[275]
Sulforaphane	[346]
Tannic acid	[347]

Tanshinone I	[287]
Tanshinone IIA	[284]
Taraxerol	[321]
Tectol	[275]
Terameprocol	[348]
Tetrahydrocannabivarin	[303]
Tetrandine	[284]
Theaflavin	[349]
Theaflavin-3,3-digallate	[280]
Theasapogenol B	[294]
Thymoquinone	[350]
Tinocordioside - <i>T. cordifolia</i> (Guduchi or Giloy)	[329]
Trichotomine	[275]
Trisjuglone	[275]
Ursolic acid	[329]
Veratridine	[284]
Vicenin	[329]
Viscosalactone B	[288]
Vitamin B12 (parent compound)	[351]
Vitamin C	[352]
Vitamin E	[351]
Withaferin A	[353]
Withanolide A	[288]
Withanolide B	[288]
Withanolide D	[288]
Withanolide E	[288]
Withanone - <i>Withania somnifera</i>	[354]
Withasomnine	[288]
Yatein	[355]

References

- [1] Upfal, J. Australian drug guide : the plain language guide to drugs and medicines of all kinds. Eighth edition. ed. Carlton, Vic., Australia, Black Inc., an imprint of Schwartz Publishing Pty Ltd, 2016.
- [2] Billett, H.H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L.R., Lo, Y., et al. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. *Thromb Haemost.* 2020, 120, 1691-9.
- [3] Seelhammer, T.G., Rowse, P., Yalamuri, S. Bivalirudin for Maintenance Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation for COVID-19. *J Cardiothorac Vasc Anesth.* 2021, 35, 1149-53.
- [4] Viecca, M., Radovanovic, D., Forleo, G.B., Santus, P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. *Pharmacological research.* 2020, 158, 104950.
- [5] Iturbe-Hernandez, T., García de Guadiana Romualdo, L., Gil Ortega, I., Martínez Francés, A., Meca Birlanga, O., Cerezo-Manchado, J.J. Dabigatran, the oral anticoagulant of choice at discharge in patients with non-valvular atrial fibrillation and COVID-19 infection: the ANIBAL protocol. *Drugs in context.* 2020, 9.
- [6] Aliter, F.K., Al-Horani, A.R. Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients. *Current Pharmaceutical Design.* 2021, 27, 866-75.
- [7] Marietta, M., Vandelli, P., Mighali, P., Vicini, R., Coluccio, V., D'Amico, R. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol. *Trials.* 2020, 21, 574.
- [8] Spaetgens, B., Nagy, M., ten Cate, H. Antiplatelet Therapy in Patients With COVID-19—More Is Less? *JAMA.* 2022, 327, 223-4.
- [9] Capell, W.H., Barnathan, E.S., Piazza, G., Spyropoulos, A.C., Hsia, J., Bull, S., et al. Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. *Am Heart J.* 2021, 235, 12-23.
- [10] Sriram, K., Insel, P.A. Proteinase-activated receptor 1: A target for repurposing in the treatment of COVID-19? *Br J Pharmacol.* 2020, 177, 4971-4.
- [11] Alkotaji, M. Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. *Int J Antimicrob Agents.* 2020, 56, 106192-.
- [12] Ansarin, K., Tolouian, R., Ardalan, M., Taghizadieh, A., Varshochi, M., Teimouri, S., et al. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. *Bioimpacts.* 2020, 10, 209-15.

- [13] Arentz, S., Hunter, J., Khamba, B., Mravunac, M., Lee, Z., Alexander, K., et al. Honeybee products for the treatment and recovery from viral respiratory infections including SARS-COV-2: A rapid systematic review. *Integr Med Res.* 2021, 10, 100779-.
- [14] Shi, Z., Puyo, C.A. N-Acetylcysteine to Combat COVID-19: An Evidence Review. *Ther Clin Risk Manag.* 2020, 16, 1047-55.
- [15] Verona Pharma Inc. Pilot Study of Ensfentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19. 2020.
- [16] Wong, H.S., Guo, C.L., Lin, G.H., Lee, K.Y., Okada, Y., Chang, W.C. Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy. *Genomics.* 2021, 113, 564-75.
- [17] Cashman, D.P. Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease. *Med Hypotheses.* 2020, 144, 110027-.
- [18] Brian C. Procter, C.R.V.P.E.S.C.H.P.A.M. Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection. *Reviews in Cardiovascular Medicine.* 2020, 21, 611-4.
- [19] Chen, F., Shi, Q., Pei, F., Vogt, A., Porritt, R.A., Garcia, G., Jr., et al. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. *Mol Syst Biol.* 2021, 17, e10239-e.
- [20] Wall, G.C., Smith, H.L., Trump, M.W., Mohr, J.D., DuMontier, S.P., Sabates, B.L., et al. Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support. *The clinical respiratory journal.* 2021, 15, 843-6.
- [21] Oddy, C., McCaul, J., Keeling, P., Allington, J., Senn, D., Soni, N., et al. Pharmacological Predictors of Morbidity and Mortality in COVID-19. *Journal of clinical pharmacology.* 2021, 61, 1286-300.
- [22] Bendjelid, K., Giraud, R., Von Düring, S. Treating hypoxemic COVID-19 "ARDS" patients with almitrine: The earlier the better? *Anaesth Crit Care Pain Med.* 2020, 39, 451-2.
- [23] Pantos, C., Kostopanagiotou, G., Armaganidis, A., Trikas, A., Tseti, I., Mourouzis, I. Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial. *Trials.* 2020, 21, 573.
- [24] Dhillon, S. Desidustat: First Approval. *Drugs.* 2022, 82, 1207-12.
- [25] Schmaier, A.A., Pajares Hurtado, G.M., Manickas-Hill, Z.J., Sack, K.D., Chen, S.M., Bhambhani, V., et al. Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. *JCI Insight.* 2021, 6, e151527.
- [26] Poloznikov, A.A., Nersisyan, S.A., Hushpulian, D.M., Kazakov, E.H., Tonevitsky, A.G., Kazakov, S.V., et al. HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons. *Front Pharmacol.* 2020, 11, 621054.
- [27] Elkahloun, A.G., Saavedra, J.M. Candesartan could ameliorate the COVID-19 cytokine storm. *Biomed Pharmacother.* 2020, 131, 110653-.
- [28] Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., Cheng, F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discov.* 2020, 6, 14-.
- [29] Yan, F., Huang, F., Xu, J., Yang, P., Qin, Y., Lv, J., et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. *Cell Discov.* 2020, 6, 77.
- [30] Rothlin, R.P., Vetulli, H.M., Duarte, M., Pelorosso, F.G. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19. *Drug Dev Res.* 2020, 81, 768-70.
- [31] Gommans, D.H.F., Nas, J., Pinto-Sietsma, S.-J., Koop, Y., Konst, R.E., Mensink, F., et al. Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute

rEspiraTORY dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease. *Am Heart J.* 2020, 226, 60-8.

[32] Si, L., Bai, H., Rodas, M., Cao, W., Oh, C.Y., Jiang, A., et al. A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. *Nat Biomed Eng.* 2021, 5, 815-29.

[33] Adebisi, Y.A., Jimoh, N.D., Ogunkola, I.O., Uwizeyimana, T., Olayemi, A.H., Ukor, N.A., et al. The use of antibiotics in COVID-19 management: a rapid review of national treatment guidelines in 10 African countries. *Tropical Medicine and Health.* 2021, 49, 51.

[34] Li, G., Yuan, M., Li, H., Deng, C., Wang, Q., Tang, Y., et al. Safety and efficacy of artemisinin-piperazine for treatment of COVID-19: an open-label, non-randomised and controlled trial. *Int J Antimicrob Agents.* 2021, 57, 106216-.

[35] Carter-Timofte, M.E., Arulanandam, R., Kurmasheva, N., Fu, K., Laroche, G., Taha, Z., et al. Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. *ACS Infect Dis.* 2021, 7, 3034-51.

[36] Oldenburg, C.E., Doan, T. Azithromycin for severe COVID-19. *The Lancet.* 2020, 396, 936-7.

[37] Tian, D., Liu, Y., Liang, C., Xin, L., Xie, X., Zhang, D., et al. An update review of emerging small-molecule therapeutic options for COVID-19. *Biomedicine & Pharmacotherapy.* 2021, 137, 111313.

[38] Alper Öztürk, A., Namlı, İ., Aygül, A. Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity. *ASSAY and Drug Development Technologies.* 2021, 19, 156-75.

[39] Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B.* 2020, 10, 766-88.

[40] Meiji Pharma Spain S.A. Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia. 2021.

[41] Lopez, A., Lakbar, I., Delamarre, L., Culver, A., Arbelot, C., Duclos, G., et al. Management of SARS-CoV-2 pneumonia in intensive care unit: An observational retrospective study comparing two bundles. *J Crit Care.* 2021, 65, 200-4.

[42] Yacouba, A., Olowo-Okere, A., Yunusa, I. Repurposing of antibiotics for clinical management of COVID-19: a narrative review. *Ann Clin Microbiol Antimicrob.* 2021, 20, 37-.

[43] Wu, C., Liu, Y., Yang, Y., Zhang, P., Zhong, W., Wang, Y., et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharmaceutica Sinica B.* 2020, 10, 766-88.

[44] Zou, L., Dai, L., Zhang, X., Zhang, Z., Zhang, Z. Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. *Arch Pharm Res.* 2020, 43, 765-72.

[45] Karampela, I., Dalamaga, M. Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? *Arch Med Res.* 2020, 51, 741-2.

[46] Yamamoto, K., Hosogaya, N., Sakamoto, N., Yoshida, H., Ishii, H., Yatera, K., et al. Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study). *BMJ Open.* 2021, 11, e053325.

[47] Olaleye, O.A., Kaur, M., Onyenaka, C., Adebuseyi, T. Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro. *Heliyon.* 2021, 7, e06426-e.

- [48] Yates, P.A., Newman, S.A., Oshry, L.J., Glassman, R.H., Leone, A.M., Reichel, E. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. *Therapeutic Advances in Respiratory Disease*. 2020, 14, 1753466620951053.
- [49] Poddighe, D., Aljofan, M. Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. *Antivir Chem Chemother*. 2020, 28, 2040206620961712-.
- [50] Jamal, Q.M.S., Ahmad, V., Alharbi, A.H., Ansari, M.A., Alzohairy, M.A., Almatroudi, A., et al. Therapeutic development by repurposing drugs targeting SARS-CoV-2 spike protein interactions by simulation studies. *Saudi J Biol Sci*. 2021, 28, 4560-8.
- [51] Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. *New England Journal of Medicine*. 2020, 384, 497-511.
- [52] Caly, L., Druce, J.D., Catton, M.G., Jans, D.A., Wagstaff, K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res*. 2020, 178, 104787.
- [53] Roostaei Firozabad, A., Meybodi, Z.A., Mousavinasab, S.R., Sahebhasagh, A., Jelodar, M.G., Karimzadeh, I., et al. Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial. *BMC infectious diseases*. 2021, 21, 297-.
- [54] Gendrot, M., Dufлот, I., Boxberger, M., Delandre, O., Jardot, P., Le Bideau, M., et al. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. *Int J Infect Dis*. 2020, 99, 437-40.
- [55] Kotta, S., Aldawsari, H.M., Badr-Eldin, S.M., Alhakamy, N.A., Md, S., Nair, A.B., et al. Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. *Frontiers in Molecular Biosciences*. 2020, 7.
- [56] Xu, J., Shi, P.-Y., Li, H., Zhou, J. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. *ACS Infect Dis*. 2020, 6, 909-15.
- [57] Rocco, P.R.M., Silva, P.L., Cruz, F.F., Junior, M.A.C.M., Tierno, P.F.G.M.M., Moura, M.A., et al. Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial. *European Respiratory Journal*. 2020, 2003725.
- [58] Alexpandi, R., De Mesquita, J.F., Pandian, S.K., Ravi, A.V. Quinolines-based SARS-CoV-2 3CL_{pro} and RdRp inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis. *Frontiers in Microbiology*. 2020, 11.
- [59] Ahmad, J., Ikram, S., Ahmad, F., Rehman, I.U., Mushtaq, M. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) – a drug repurposing study. *Heliyon*. 2020, 6, e04502.
- [60] Roy Chattopadhyay, N., Chatterjee, K., Banerjee, A., Choudhuri, T. Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters. *Virusdisease*. 2020, 31, 1-11.
- [61] Puhl, A.C., Fritch, E.J., Lane, T.R., Tse, L.V., Yount, B.L., Sacramento, C.Q., et al. Repurposing the Ebola and Marburg Virus inhibitors tilorone, quinacrine, and pyronaridine: in vitro activity against SARS-CoV-2 and potential mechanisms. *ACS Omega*. 2021, 6, 7454-68.
- [62] Younis, N.K., Zareef, R.O., Al Hassan, S.N., Bitar, F., Eid, A.H., Arabi, M. Hydroxychloroquine in COVID-19 Patients: Pros and Cons. *Front Pharmacol*. 2020, 11, 597985-.
- [63] Husain, A., Byrareddy, S.N. Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. *Chem Biol Interact*. 2020, 331, 109282-.
- [64] Prof. Dr. Shohael Mahmud Arafat. Role of Co-trimoxazole in Severe COVID-19 Patients. 2020.

- [65] Persoons, L., Vanderlinden, E., Vangeel, L., Wang, X., Do, N.D.T., Foo, S.-Y.C., et al. Broad spectrum anti-coronavirus activity of a series of anti-malaria quinoline analogues. *Antiviral Res.* 2021, 193, 105127-.
- [66] Stachulski, A.V., Taujanskas, J., Pate, S.L., Rajoli, R.K.R., Aljayyousi, G., Pennington, S.H., et al. Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? *ACS Infect Dis.* 2021, 7, 1317-31.
- [67] Schein, C.H. Repurposing approved drugs for cancer therapy. *Br Med Bull.* 2021, 137, 13-27.
- [68] Rutsaert, S., Steens, J.M., Gineste, P., Cole, B., Kint, S., Barrett, P.N., et al. Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study. *Journal of virus eradication.* 2019, 5, 10-22.
- [69] Roschewski, M., Lionakis Michail, S., Sharman Jeff, P., Roswarski, J., Goy, A., Monticelli, M.A., et al. Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Science Immunology.* 2020, 5, eabd0110.
- [70] Levitt, J.E., Hedlin, H., Duong, S., Lu, D., Lee, J., Bunning, B., et al. Evaluation of acebilustat, a selective inhibitor of leukotriene B4 biosynthesis, for treatment of outpatients with mild-moderate COVID-19 disease: A randomized, double-blind, placebo- controlled Phase 2 trial. *Clin Infect Dis.* 2023.
- [71] Bianconi, V., Violi, F., Fallarino, F., Pignatelli, P., Sahebkar, A., Pirro, M. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? *Drugs.* 2020, 80, 1383-96.
- [72] Geiger, J.D., Khan, N., Murugan, M., Boison, D. Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities. *Front Pharmacol.* 2020, 11.
- [73] Wells, J.M. COVID-19 Study of Safety and Tolerability of Alvelestat (COSTA). 2020.
- [74] Khan, N.A. Anakinra for severe forms of COVID-19. *The Lancet Rheumatology.* 2020, 2, e586-e7.
- [75] Angion Biomedica Corp. Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia. 2020.
- [76] Olisova, O.Y., Anpilogova, E.M., Svistunova, D.A. Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient. *Dermatol Ther.* 2020, 33, e13668-e.
- [77] Coyle, J., Igbinomwanhia, E., Sanchez-Nadales, A., Danciu, S., Chu, C., Shah, N. A Recovered Case of COVID-19 Myocarditis and ARDS Treated With Corticosteroids, Tocilizumab, and Experimental AT-001. *JACC: Case Reports.* 2020, 2, 1331-6.
- [78] Gordon, D., Hellriegel, E.T., Hope, H.R., Burt, D., Monahan, J.B. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the MK2 inhibitor ATI-450 in healthy subjects: a placebo-controlled, randomized phase 1 study. *Clin Pharmacol.* 2021, 13, 123-34.
- [79] Rodriguez-Nava, G., Trelles-Garcia, D.P., Yanez-Bello, M.A., Chung, C.W., Trelles-Garcia, V.P., Friedman, H.J. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. *Critical Care.* 2020, 24, 429.
- [80] Schreiber, A., Viemann, D., Schöning, J., Schloer, S., Mecate Zambrano, A., Brunotte, L., et al. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. *Cellular and Molecular Life Sciences.* 2022, 79, 65.
- [81] Galera Therapeutics Inc. A Trial of GC4419 in Patients With Critical Illness Due to COVID-19. 2020.
- [82] McCafferty, K., Hollowood, Z., Allen, M., Lockhart, D., Chorlton, J., Martin, J. ARCADIA study protocol: a phase II, randomised, double-blind, placebo-controlled clinical

trial to assess the safety and efficacy of AZD1656 in patients with diabetes hospitalised with suspected or confirmed COVID-19. *BMJ open*. 2021, 11, e049650-e.

[83] Kalil, A.C., Patterson, T.F., Mehta, A.K., Tomashek, K.M., Wolfe, C.R., Ghazaryan, V., et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. *New England Journal of Medicine*. 2020, 384, 795-807.

[84] BioAge Labs Inc. Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure. 2021.

[85] Shen, X.B., Chen, X., Zhang, Z.Y., Wu, F.F., Liu, X.H. Cathepsin C inhibitors as anti-inflammatory drug discovery: Challenges and opportunities. *European Journal of Medicinal Chemistry*. 2021, 225, 113818.

[86] Oliver, J.C., Silva, E.N., Soares, L.M., Scodeler, G.C., Santos, A.S., Corsetti, P.P., et al. Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus. *Ther Adv Vaccines Immunother*. 2022, 10, 25151355221144845.

[87] Yu, L.-M., Bafadhel, M., Dorward, J., Hayward, G., Saville, B.R., Gbinigie, O., et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet*. 2021, 398, 843-55.

[88] Frank, M. Bucillamine in the treatment of patients with mild to moderate COVID-19: an interview with Michael Frank. *Future Microbiol*. 2022, 17, 157-9.

[89] Skayem, C., Ayoub, N. Carvedilol and COVID-19: A Potential Role in Reducing Infectivity and Infection Severity of SARS-CoV-2. *Am J Med Sci*. 2020, 360, 300-.

[90] Baghaki, S., Yalcin, C.E., Baghaki, H.S., Aydin, S.Y., Daghan, B., Yavuz, E. COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies. *International Journal of Infectious Diseases*. 2020, 101, 29-32.

[91] Okamoto, M., Toyama, M., Baba, M. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res*. 2020, 182, 104902-.

[92] Plaze, M., Attali, D., Petit, A.C., Blatzer, M., Simon-Loriere, E., Vinckier, F., et al. Repurposing chlorpromazine to treat COVID-19: The reCoVery study. *Encephale*. 2020, 46, 169-72.

[93] Mori, N., Katayama, M., Nukaga, S. Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. *J Microbiol Immunol Infect*. 2021, 54, 109-12.

[94] Miller, J., Bruen, C., Schnaus, M., Zhang, J., Ali, S., Lind, A., et al. Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial. *Crit Care*. 2020, 24, 502-.

[95] Yousefi, H., Mashouri, L., Okpechi, S.C., Alahari, N., Alahari, S.K. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. *Biochemical pharmacology*. 2021, 183, 114296-.

[96] Gálvez-Romero, J.L., Palmeros-Rojas, O., Real-Ramírez, F.A., Sánchez-Romero, S., Tome-Maxil, R., Ramírez-Sandoval, M.P., et al. Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study. *J Intern Med*. 2021, 289, 906-20.

[97] Kosiborod, M., Berwanger, O., Koch, G.G., Martinez, F., Mukhtar, O., Verma, S., et al. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. *Diabetes, Obesity and Metabolism*. 2021, 23, 886-96.

- [98] Quagliariello, V., Bonelli, A., Caronna, A., Lombardi, M.C., Conforti, G., Libutti, M., et al. SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications? *European review for medical and pharmacological sciences*. 2020, 24, 9169-71.
- [99] Group, R.C., Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*. 2021, 384, 693-704.
- [100] Zhao, H., Davies, R., Ma, D. Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU. *Br J Anaesth*. 2021, 126, e33-e5.
- [101] Madurka, I., Vishnevsky, A., Soriano, J.B., Gans, S.J., Ore, D.J.S., Rendon, A., et al. DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function. *Infection*. 2022, 1-14.
- [102] Dowarah, J., Marak, B.N., Yadav, U.C.S., Singh, V.P. Potential drug development and therapeutic approaches for clinical intervention in COVID-19. *Bioorg Chem*. 2021, 114, 105016.
- [103] Palma, G., Pasqua, T., Silvestri, G., Rocca, C., Gualtieri, P., Barbieri, A., et al. PI3K δ Inhibition as a Potential Therapeutic Target in COVID-19. *Frontiers in Immunology*. 2020, 11.
- [104] Enzychem Lifesciences Corporation. To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia. 2020.
- [105] Reznik, S.E., Tiwari, A.K., Ashby, C.R., Jr. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome? *Pharmacological research*. 2020, 160, 105055-.
- [106] Hoertel, N., Sánchez-Rico, M., Vernet, R., Beeker, N., Jannot, A.-S., Neuraz, A., et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. *Molecular Psychiatry*. 2021, 26, 5199-212.
- [107] Janowitz, T., Gablenz, E., Pattinson, D., Wang, T.C., Conigliaro, J., Tracey, K., et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. *Gut*. 2020, 69, 1592.
- [108] Orienti, I., Gentilomi, G.A., Farruggia, G. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19. *Int J Mol Sci*. 2020, 21, 3812.
- [109] Teymouri, S., Pourbayram Kaleybar, S., Hejazian, S.S., Hejazian, S.M., Ansarin, K., Ardalan, M., et al. The effect of Fingolimod on patients with moderate to severe COVID-19. *Pharmacology Research & Perspectives*. 2023, 11, e01039.
- [110] Nakazono, A., Nakamaru, Y., Ramezanpour, M., Kondo, T., Watanabe, M., Hatakeyama, S., et al. Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells. *Frontiers in cellular and infection microbiology*. 2021, 11, 655666.
- [111] Lenze, E.J., Mattar, C., Zorumski, C.F., Stevens, A., Schweiger, J., Nicol, G.E., et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *JAMA*. 2020, 324, 2292-300.
- [112] Strich, J.R., Ramos-Benitez, M.J., Randazzo, D., Stein, S.R., Babyak, A., Davey, R.T., et al. Fostamatinib inhibits neutrophils extracellular traps induced by COVID-19 patient plasma: a potential therapeutic. *The Journal of Infectious Diseases*. 2021, 223, 981-4.
- [113] Foresee Pharmaceuticals Co Ltd. A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS). 2021.
- [114] Brennecke, A., Villar, L., Wang, Z., Doyle, L.M., Meek, A., Reed, M., et al. Is Inhaled Furosemide a Potential Therapeutic for COVID-19? *Am J Med Sci*. 2020, 360, 216-21.

- [115] Mishra, G.P., Mulani, J. Corticosteroids for COVID-19: the search for an optimum duration of therapy. *The Lancet Respiratory Medicine*. 2021, 9, e8.
- [116] Treon, S.P., Castillo, J.J., Skarbnik, A.P., Soumerai, J.D., Ghobrial, I.M., Guerrero, M.L., et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. *Blood*. 2020, 135, 1912-5.
- [117] MediciNova. Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS. 2020.
- [118] Algernon Pharmaceuticals. Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease. 2020.
- [119] Emadi, A., Chua, J.V., Talwani, R., Bentzen, S.M., Baddley, J. Safety and efficacy of imatinib for hospitalized adults with COVID-19: a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020, 21, 897.
- [120] Sofia Magdalena, T., Juan José Nieto, F., Samuel, C., Morten, H., Asger, S., Celeste, P., et al. Imiquimod shows anti-viral actions in human bronchial epithelium - implications for COVID-19 treatment. *European Respiratory Journal*. 2021, 58, PA2136.
- [121] Marinella, M.A. Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19. *Int J Clin Pract*. 2020, 74, e13535-e.
- [122] Meng, X., Ling, Y., Zhang, L., Zhang, Q., Dong, P., Zhu, T., et al. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. *Bioscience trends*. 2020, 14, 161-7.
- [123] Finnerty, D.T., Buggy, D.J. A novel role for lidocaine in COVID-19 patients? *Br J Anaesth*. 2020, 125, e391-e4.
- [124] Fulcrum Therapeutics. Losmapimod Safety and Efficacy in COVID-19 (LOSVID). 2020.
- [125] Vlach, J., Bender, A.T., Przetak, M., Pereira, A., Deshpande, A., Johnson, T., et al. Discovery of M5049: a novel selective TLR7/8 inhibitor for treatment of autoimmunity. *Journal of Pharmacology and Experimental Therapeutics*. 2020, JPET-AR-2020-000275.
- [126] Shamsi, A., Mohammad, T., Anwar, S., AlAjmi, M.F., Hussain, A., Rehman, M.T., et al. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. *Biosci Rep*. 2020, 40, BSR20201256.
- [127] Bahrapour Juybari, K., Pourhanifeh, M.H., Hosseinzadeh, A., Hemati, K., Mehrzadi, S. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. *Virus Res*. 2020, 287, 198108-.
- [128] Kjeldsen, S., Nielsen, J., Mertz Nørgård, B., Kjeldsen, J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. *Inflamm Bowel Dis*. 2022, 28, 1513-9.
- [129] Dardano, A., Del Prato, S. Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19? *The Lancet Healthy Longevity*. 2021, 2, e6-e7.
- [130] May, B.C., Gallivan, K.H. Levocetirizine and montelukast in the COVID-19 treatment paradigm. *International immunopharmacology*. 2021, 103, 108412-.
- [131] Tran, L., Kurkinen, M. Alzheimer drug candidate NA-831 for the treatment of Dementia caused by Covid-19- A Phase 2/3 clinical trial methodology. *Alzheimer's & Dementia*. 2022, 18, e066242.
- [132] Choubey, A., Dehury, B., Kumar, S., Medhi, B., Mondal, P. Naltrexone a potential therapeutic candidate for COVID-19. *J Biomol Struct Dyn*. 2020, 1-8.
- [133] Kiani, P., Scholey, A., Dahl, T.A., McMann, L., Iversen, J.M., Verster, J.C. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. *Viruses*. 2021, 13, 558.
- [134] George, P.M., Wells, A.U., Jenkins, R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. *Lancet Respir Med*. 2020, 8, 807-15.

- [135] Ebrahimi, S.A. Noscipine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2. *Drug Dev Res.* 2020, 81, 765-7.
- [136] Smith, C.D., Maines, L.W., Keller, S.N., Katz Ben-Yair, V., Fathi, R., Plasse, T.F., et al. Recent Progress in the Development of Opaganib for the Treatment of Covid-19. *Drug Des Devel Ther.* 2022, 16, 2199-211.
- [137] Pawelczyk, A., Zaprutko, L. Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives. *Future Med Chem.* 2020, 12, 1743-57.
- [138] López-Iranzo, J.F., López-Rodas, M.A., Franco, L., López-Rodas, G. Pentoxifylline and Oxypurinol: Potential Drugs to Prevent the “Cytokine Release (Storm) Syndrome” Caused by SARS-CoV-2? *Current Pharmaceutical Design.* 2020, 26, 4515-21.
- [139] Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec. COVID-19 Ozanimod Intervention Study (COZI). 2020.
- [140] Cafardi, J., Miller, C., Terebelo, H., Tewell, C., Benzaquen, S., Park, D., et al. Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial. *JAMA Network Open.* 2022, 5, e2242918-e.
- [141] Seirafianpour, F., Mozafarpour, S., Fattahi, N., Sadeghzadeh-Bazargan, A., Hanifiha, M., Goodarzi, A. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? *Dermatol Ther.* 2020, 33, e13733-e.
- [142] Danto, S.I., Shojaee, N., Singh, R.S.P., Li, C., Gilbert, S.A., Manukyan, Z., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. *Arthritis Res Ther.* 2019, 21, 269-.
- [143] Can-Fite BioPharma. Piclidenoson for Treatment of COVID-19. 2020.
- [144] Myall, K.J., Mukherjee, B., Castanheira, A.M., Lam, J.L., Benedetti, G., Mak, S.M., et al. Persistent Post-COVID-19 Interstitial Lung Disease. An Observational Study of Corticosteroid Treatment. *Ann Am Thorac Soc.* 2021, 18, 799-806.
- [145] Cecon, E., Isabelle, C., Poder, S.L., Real, F., Zhu, A., Tu, L., et al. Therapeutic potential of melatonin and melatonergic drugs on K18-hACE2 mice infected with SARS-CoV-2. *J Pineal Res.* 2022, 72, e12772-e.
- [146] Li, H.-H., Liu, C.-C., Hsu, T.-W., Lin, J.-H., Hsu, J.-W., Li, A.F.-Y., et al. Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19. *Part Fibre Toxicol.* 2021, 18, 11-.
- [147] Rossi, R., Talarico, M., Coppi, F., Boriani, G. Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action. *Intern Emerg Med.* 2020, 15, 1573-6.
- [148] D'Alessio, A., Del Poggio, P., Bracchi, F., Cesana, G., Sertori, N., Di Mauro, D., et al. Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. *Leukemia.* 2021, 35, 635-8.
- [149] Restorbio Inc. A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults. 2020.
- [150] Estrada, E. Protein-driven mechanism of multiorgan damage in COVID-19. *Med Drug Discov.* 2020, 100069-.
- [151] Bischof, E., Siow, R.C., Zhavoronkov, A., Kaeberlein, M. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. *The Lancet Healthy Longevity.* 2021, 2, e105-e11.
- [152] Solanich, X., Antolí, A., Padullés, N., Fanlo-Maresma, M., Iriarte, A., Mitjavila, F., et al. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe

pneumonia secondary to COVID-19: The TACROVID trial protocol. Contemporary clinical trials communications. 2021, 21, 100716.

[153] Singh, D., Bogus, M., Moskalenko, V., Lord, R., Moran, E.J., Crater, G.D., et al. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. *European Respiratory Journal*. 2021, 2100673.

[154] Maio, N., Cherry, S., Schultz, D.C., Hurst, B.L., Linehan, W.M., Rouault, T.A. TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model. *iScience*. 2022, 25, 105074.

[155] Khalil, A., Kamar, A., Nemer, G. Thalidomide-Revisited: Are COVID-19 Patients Going to Be the Latest Victims of Yet Another Theoretical Drug-Repurposing? *Frontiers in Immunology*. 2020, 11.

[156] Guimarães, P.O., Quirk, D., Furtado, R.H., Maia, L.N., Saraiva, J.F., Antunes, M.O., et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. *New England Journal of Medicine*. 2021, 385, 406-15.

[157] Vanda Pharmaceuticals. ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection. 2020.

[158] El-Ashmawy, N.E., Lashin, A.-H.A., Okasha, K.M., Abo Kamer, A.M., Mostafa, T.M., El-Aasr, M., et al. The plausible mechanisms of tramadol for treatment of COVID-19. *Med Hypotheses*. 2021, 146, 110468.

[159] van den Berg, D.F., te Velde, A.A. Severe COVID-19: NLRP3 inflammasome dysregulated. *Frontiers in Immunology*. 2020, 11.

[160] Huang, H., Hu, P.F., Sun, L.L., Guo, Y.B., Wang, Q., Liu, Z.M., et al. Treatment of patients with Covid-19 with a high dose of ulinastatin. *Experimental and therapeutic medicine*. 2022, 23, 121.

[161] Vascular Biogenics Ltd. operating as VBL Therapeutics. A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19. 2021.

[162] Fagone, P., Muthumani, K., Mangano, K., Magro, G., Meroni, P.L., Kim, J.J., et al. VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. *Immunology*. 2014, 142, 594-602.

[163] Biohaven Pharmaceuticals Inc. Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen. 2020.

[164] Serra, A., Fratello, M., Federico, A., Ojha, R., Provenzani, R., Tasnadi, E., et al. Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation. *Briefings in Bioinformatics*. 2021, bbab507.

[165] D. E. Shaw Research. "Molecular Dynamics Simulations Related to SARS-CoV-2," D. E. Shaw Research Technical Data, 2020. http://www.deshawresearch.com/resources_sarscov2.html.

[166] Castaldo, N., Aimo, A., Castiglione, V., Padalino, C., Emdin, M., Tascini, C. Safety and efficacy of amiodarone in a patient with COVID-19. *JACC Case Rep*. 2020, 2, 1307-10.

[167] Baranov, M.V., Bianchi, F., van den Bogaart, G. The PIKfyve inhibitor apilimod: a double-edged sword against COVID-19. *Cells*. 2020, 10, 30.

[168] Wilkinson, T., Dixon, R., Page, C., Carroll, M., Griffiths, G., Ho, L.-P., et al. ACCORD: A multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020, 21, 691-.

[169] Goren, A., Wambier, C.G., Herrera, S., McCoy, J., Vaño-Galván, S., Gioia, F., et al. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. *J Eur Acad Dermatol Venereol*. 2021, 35, e13-e5.

- [170] Welén, K., Rosendal, E., Gisslén, M., Lenman, A., Freyhult, E., Fonseca-Rodríguez, O., et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. *European Urology*. 2022, 81, 285-93.
- [171] Çağla Begüm, A., Gözde, Ç., Gökçe, C.-Ü. Small-molecule antiviral agents in ongoing clinical trials for COVID-19. *Current Drug Targets*. 2021, 22, 1-20.
- [172] Bakovic, A., Risner, K., Bhalla, N., Alem, F., Chang, T.L., Weston, W.K., et al. Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture. *Viruses*. 2021, 13, 271.
- [173] Breining, P., Frølund, A.L., Højen, J.F., Gunst, J.D., Staerke, N.B., Saedder, E., et al. Camostat mesylate against SARS-CoV-2 and COVID-19—Rationale, dosing and safety. *Basic & Clinical Pharmacology & Toxicology*. 2021, 128, 204-12.
- [174] Tobback, E., Degroote, S., Buysse, S., Delesie, L., Van Dooren, L., Vanherrewege, S., et al. Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial. *Int J Infect Dis*. 2022, 122, 628-35.
- [175] Cheng, Y.-W., Chao, T.-L., Li, C.-L., Chiu, M.-F., Kao, H.-C., Wang, S.-H., et al. Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects. *Cell Rep*. 2020, 33, 108254-.
- [176] Wu, C., Zheng, M., Yang, Y., Gu, X., Yang, K., Li, M., et al. Furin: a potential therapeutic target for COVID-19. *iScience*. 2020, 23, 101642.
- [177] Peralta-Garcia, A., Torrens-Fontanals, M., Stepniewski, T.M., Grau-Expósito, J., Perea, D., Ayinampudi, V., et al. Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. *Int J Mol Sci*. 2021, 22, 13592.
- [178] Li, F., Han, M., Dai, P., Xu, W., He, J., Tao, X., et al. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. *Nature Communications*. 2021, 12, 866.
- [179] Yasmin, F., Zeeshan, M.H., Ullah, I. The role of fenofibrate in the treatment of COVID-19. *Ann Med Surg (Lond)*. 2021, 102974-.
- [180] Trezza, A., Iovinelli, D., Santucci, A., Prischi, F., Spiga, O. An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. *Scientific Reports*. 2020, 10, 13866.
- [181] Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. *Nature*. 2020, 586, 113-9.
- [182] Costanzi, E., Kuzikov, M., Esposito, F., Albani, S., Demitri, N., Giabbai, B., et al. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L. *Int J Mol Sci*. 2021, 22, 11779.
- [183] Bestle, D., Heindl, M.R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. *Life Sci Alliance*. 2020, 3, e202000786.
- [184] Takahashi, W., Yoneda, T., Koba, H., Ueda, T., Tsuji, N., Ogawa, H., et al. Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation. *Int J Infect Dis*. 2021, 102, 529-31.
- [185] Quinn, T.M., Gaughan, E.E., Bruce, A., Antonelli, J., O'Connor, R., Li, F., et al. Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. *eBioMedicine*. 2022, 76.
- [186] Scalise, M., Indiveri, C. Repurposing nimesulide, a potent inhibitor of the B0AT1 subunit of the SARS-CoV-2 receptor, as a therapeutic adjuvant of COVID-19. *SLAS DISCOVERY: Advancing the Science of Drug Discovery*. 2020, 25, 1171-3.

- [187] Prabhakara, C., Godbole, R., Sil, P., Jahnavi, S., Gulzar, S.-e.-J., van Zanten, T.S., et al. Strategies to target SARS-CoV-2 entry and infection using dual mechanisms of inhibition by acidification inhibitors. *PLOS Pathogens*. 2021, 17, e1009706.
- [188] Hempel, T., Elez, K., Krüger, N., Raich, L., Shrimp, J.H., Danov, O., et al. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties. *Chem Sci*. 2021, 12, 12600-9.
- [189] McCoy, J., Goren, A., Cadegiani, F.A., Vaño-Galván, S., Kovacevic, M., Situm, M., et al. Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial. *Front Med (Lausanne)*. 2021, 8, 668698-.
- [190] Cadegiani, F.A., Goren, A., Wambier, C.G. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). *Med Hypotheses*. 2020, 143, 110112.
- [191] Al Adem, K., Shanti, A., Stefanini, C., Lee, S. Inhibition of SARS-CoV-2 entry into host cells using small molecules. *Pharmaceuticals (Basel)*. 2020, 13, 447.
- [192] Nojomi, M., Yassin, Z., Keyvani, H., Makiani, M.J., Roham, M., Laali, A., et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. *BMC Infectious Diseases*. 2020, 20, 954.
- [193] Hattori, S.-i., Higashi-Kuwata, N., Hayashi, H., Allu, S.R., Raghavaiah, J., Bulut, H., et al. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. *Nature Communications*. 2021, 12, 668.
- [194] Chou, C.-Y., Chien, C.-H., Han, Y.-S., Prebanda, M.T., Hsieh, H.-P., Turk, B., et al. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. *Biochemical Pharmacology*. 2008, 75, 1601-9.
- [195] Ann, H., Kim, K.H., Choi, H.Y., Chang, H.H., Han, S.H., Kim, K.H., et al. Safety and efficacy of ziagen (abacavir sulfate) in HIV-infected Korean patients. *Infect Chemother*. 2017, 49, 205-12.
- [196] Pott Junior, H., de Oliveira, M.F.B., Gambero, S., Amazonas, R.B. Randomized clinical trial of famciclovir or acyclovir for the treatment of herpes zoster in adults. *International Journal of Infectious Diseases*. 2018, 72, 11-5.
- [197] Dando, T.M., Plosker, G.L. Adefovir dipivoxil. *Drugs*. 2003, 63, 2215-34.
- [198] Zhang, L., Lin, D., Kusov, Y., Nian, Y., Ma, Q., Wang, J., et al. α -Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment. *Journal of Medicinal Chemistry*. 2020, 63, 4562-78.
- [199] Pawlotsky, J.-M. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. *Clinical Infectious Diseases*. 2020, 71, 2191-4.
- [200] Araújo, R., Aranda-Martínez, J.D., Aranda-Abreu, G.E. Amantadine treatment for people with COVID-19. *Arch Med Res*. 2020, 51, 739-40.
- [201] Gonzalez-Martinez, A., Guerrero-Peral Á, L., Arias-Rivas, S., Silva, L., Sierra, Á., Gago-Veiga, A.B., et al. Amitriptyline for post-COVID headache: effectiveness, tolerability, and response predictors. *J Neurol*. 2022, 269, 5702-9.
- [202] Zhu, H., Chen, C.Z., Sakamuru, S., Zhao, J., Ngan, D.K., Simeonov, A., et al. Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. *Scientific Reports*. 2021, 11, 6725.
- [203] Soremekun, O.S., Omolabi, K.F., Adewumi, A.T., Soliman, M.E.S. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective. *Future Science OA*. 2020, 7, FSO640.

- [204] Tompa, D.R., Immanuel, A., Srikanth, S., Kadirvel, S. Trends and strategies to combat viral infections: a review on FDA approved antiviral drugs. *International Journal of Biological Macromolecules*. 2021, 172, 524-41.
- [205] Good Steven, S., Westover, J., Jung Kie, H., Zhou, X.-J., Moussa, A., La Colla, P., et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. *Antimicrobial Agents and Chemotherapy*. 65, e02479-20.
- [206] Berliba, E., Bogus, M., Vanhoutte, F., Berghmans, P.-J., Good Steven, S., Moussa, A., et al. Safety, pharmacokinetics, and antiviral activity of AT-527, a novel purine nucleotide prodrug, in Hepatitis C virus-infected subjects with or without cirrhosis. *Antimicrobial Agents and Chemotherapy*. 63, e01201-19.
- [207] Fintelman-Rodrigues, N., Sacramento Carolina, Q., Ribeiro Lima, C., Souza da Silva, F., Ferreira André, C., Mattos, M., et al. Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production. *Antimicrobial Agents and Chemotherapy*. 64, e00825-20.
- [208] Reznikov, L.R., Norris, M.H., Vashisht, R., Bluhm, A.P., Li, D., Liao, Y.-S.J., et al. Identification of antiviral antihistamines for COVID-19 repurposing. *Biochem Biophys Res Commun*. 2021, 538, 173-9.
- [209] Yu, B., Chang, J. Azvudine (FNC): a promising clinical candidate for COVID-19 treatment. *Signal Transduction and Targeted Therapy*. 2020, 5, 236.
- [210] Biering, S.B., Van Dis, E., Wehri, E., Yamashiro, L.H., Nguyenla, X., Dugast-Darzacq, C., et al. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2. *ACS Infect Dis*. 2021, 7, 2337-51.
- [211] Teoh, S.L., Lim, Y.H., Lai, N.M., Lee, S.W.H. Directly acting antivirals for COVID-19: where do we stand? 2020, 11.
- [212] Lou, Y., Liu, L., Yao, H., Hu, X., Su, J., Xu, K., et al. Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial. *European Journal of Pharmaceutical Sciences*. 2021, 157, 105631.
- [213] Sun, Q., Ye, F., Liang, H., Liu, H., Li, C., Lu, R., et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. *Signal Transduction and Targeted Therapy*. 2021, 6, 212.
- [214] Schultz, D.C., Johnson, R.M., Ayyanathan, K., Miller, J., Whig, K., Kamalia, B., et al. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. *Nature*. 2022.
- [215] Vatansever, E.C., Yang, K.S., Drelich, A.K., Kratch, K.C., Cho, C.-C., Kempaiah, K.R., et al. Bepridil is potent against SARS-CoV-2 in vitro. *Proceedings of the National Academy of Sciences*. 2021, 118, e2012201118.
- [216] Sun, C., Zhang, J., Wei, J., Zheng, X., Zhao, X., Fang, Z., et al. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein. *PLOS ONE*. 2021, 16, e0245975.
- [217] Fu, L., Ye, F., Feng, Y., Yu, F., Wang, Q., Wu, Y., et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. *Nature communications*. 2020, 11, 4417-.
- [218] Coelho, A.R., Oliveira, P.J. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection. *Eur J Clin Invest*. 2020, 50, e13366-e.
- [219] Rabasseda, X. Brivudine: A herpes virostatic with rapid antiviral activity and once-daily dosing. *Drugs of today (Barcelona, Spain : 1998)*. 2003, 39, 359-71.

- [220] Jin, Z., Zhao, Y., Sun, Y., Zhang, B., Wang, H., Wu, Y., et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. *Nature Structural & Molecular Biology*. 2020, 27, 529-32.
- [221] Clarke, E.C., Nofchissey, R.A., Ye, C., Bradfute, S.B. The iminosugars celgosivir, castanospermine and UV-4 inhibit SARS-CoV-2 replication. *Glycobiology*. 2021, 31, 378-84.
- [222] Al-Horani, R.A., Kar, S. Potential anti-SARS-CoV-2 therapeutics that target the post-entry stages of the viral life cycle: a comprehensive review. *Viruses*. 2020, 12, 1092.
- [223] Chen, J., Xia, L., Liu, L., Xu, Q., Ling, Y., Huang, D., et al. Antiviral activity and safety of darunavir/cobicistat for the treatment of COVID-19. *Open Forum Infectious Diseases*. 2020, 7.
- [224] Shen, Z., Ratia, K., Cooper, L., Kong, D., Lee, H., Kwon, Y., et al. Potent, novel SARS-CoV-2 PLpro inhibitors block viral replication in monkey and human cell cultures. *bioRxiv*. 2021, 2021.02.13.431008.
- [225] Chan, H.-T., Chao, C.-M., Lai, C.-C. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis. *Journal of Infection*. 2021, 82, e34-e5.
- [226] Chen, H., Zhang, Z., Wang, L., Huang, Z., Gong, F., Li, X., et al. First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients. *Medicine (Baltimore)*. 2020, 99, e23357-e.
- [227] Ali, N., Prasad, K., AlAsmari, A.F., Alharbi, M., Rashid, S., Kumar, V. Genomics-guided targeting of stress granule proteins G3BP1/2 to inhibit SARS-CoV-2 propagation. *International journal of biological macromolecules*. 2021, 190, 636-48.
- [228] Lin, M.-H., Moses, D.C., Hsieh, C.-H., Cheng, S.-C., Chen, Y.-H., Sun, C.-Y., et al. Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. *Antiviral Res*. 2018, 150, 155-63.
- [229] Weglarz-Tomczak, E., Tomczak, J.M., Talma, M., Burda-Grabowska, M., Giurg, M., Brul, S. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. *Scientific Reports*. 2021, 11, 3640.
- [230] Sax, P.E., Rockstroh, J.K., Luetkemeyer, A.F., Yazdanpanah, Y., Ward, D., Trottier, B., et al. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in virologically suppressed adults with Human Immunodeficiency Virus. *Clin Infect Dis*. 2021, 73, e485-e93.
- [231] Boltz, D., Peng, X., Muzzio, M., Dash, P., Thomas, P.G., Margitich, V. Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. *Antivir Chem Chemother*. 2018, 26, 2040206618811416-.
- [232] Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., et al. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. *Antimicrobial Agents and Chemotherapy*. 2022, 66, e00697-22.
- [233] Indu, P., Rameshkumar, M.R., Arunagirinathan, N., Al-Dhabi, N.A., Valan Arasu, M., Ignacimuthu, S. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. *J Infect Public Health*. 2020, 13, 1856-61.
- [234] Mullen, P.J., Garcia, G., Purkayastha, A., Matulionis, N., Schmid, E.W., Momcilovic, M., et al. SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. *Nature Communications*. 2021, 12, 1876.
- [235] Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., Martinez-de-Hoyo, R. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. *Scientific Reports*. 2021, 11, 11022.
- [236] Torres, H.A., Arduino, R.C. Fosamprenavir calcium plus ritonavir for HIV infection. *Expert Review of Anti-infective Therapy*. 2007, 5, 349-63.

- [237] Julander, J.G., Demarest, J.F., Taylor, R., Gowen, B.B., Walling, D.M., Mathis, A., et al. An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral. *Antiviral Res.* 2021, 195, 105180.
- [238] Rolling, K.E., Jorgenson, M.R., Descourouez, J.L., Mandelbrot, D.A., Redfield, R.R., Smith, J.A. Ganciclovir-resistant cytomegalovirus infection in abdominal solid organ transplant recipients: case series and review of the literature. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.* 2017, 37, 1258-71.
- [239] Halfon, P., Bestion, E., Zandi, K., Andreani, J., Baudoin, J.-P., La Scola, B., et al. GNS561 exhibits potent in vitro antiviral activity against SARS-CoV-2 through autophagy inhibition. *bioRxiv.* 2020, 2020.10.06.327635.
- [240] Sulejmani, N., Jafri, S.-M. Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy. *Hepat Med.* 2018, 10, 33-42.
- [241] Karaoui, L.R., Mansour, H., Chahine, E.B. Elbasvir–grazoprevir: A new direct-acting antiviral combination for hepatitis C. *American Journal of Health-System Pharmacy.* 2017, 74, 1533-40.
- [242] Fu, Z., Huang, B., Tang, J., Liu, S., Liu, M., Ye, Y., et al. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery. *Nature Communications.* 2021, 12, 488.
- [243] Hahn, F., Wangen, C., Häge, S., Peter, A.S., Dobler, G., Hurst, B., et al. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. *Viruses.* 2020, 12, 1394.
- [244] Ikematsu, H., Kawai, N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. *Expert Review of Anti-infective Therapy.* 2011, 9, 851-7.
- [245] Chen, Y.W., Yiu, C.-P.B., Wong, K.-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. *F1000Res.* 2020, 9, 129-.
- [246] Wang, Q., Guo, H., Li, Y., Jian, X., Hou, X., Zhong, N., et al. Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study. *Front Pharmacol.* 2021, 12, 581833-.
- [247] Horby, P.W., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Emberson, J., et al. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *The Lancet.* 2020, 396, 1345-52.
- [248] Drayman, N., DeMarco Jennifer, K., Jones Krysten, A., Azizi, S.-A., Froggatt Heather, M., Tan, K., et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. *Science.* 2021, 373, 931-6.
- [249] Şimşek-Yavuz, S., Komsuoğlu Çelikyurt, F.I. An update of anti-viral treatment of COVID-19. *Turk J Med Sci.* 2021, 51, 3372-90.
- [250] Holman, W., Holman, W., McIntosh, S., Painter, W., Painter, G., Bush, J., et al. Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2. *Trials.* 2021, 22, 561.
- [251] Bai, Y., Ye, F., Feng, Y., Liao, H., Song, H., Qi, J., et al. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug nardaprevir. *Signal Transduction and Targeted Therapy.* 2021, 6, 51.
- [252] Musarrat, F., Chouljenko, V., Dahal, A., Nabi, R., Chouljenko, T., Jois, S.D., et al. The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARS-CoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections. *J Med Virol.* 2020, 92, 2087-95.

- [253] Tan, Q., Duan, L., Ma, Y., Wu, F., Huang, Q., Mao, K., et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. *Bioorg Chem.* 2020, 104, 104257-.
- [254] de Vries, M., Mohamed Adil, S., Prescott Rachel, A., Valero-Jimenez Ana, M., Desvignes, L., O'Connor, R., et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19. *Journal of Virology.* 95, e01819-20.
- [255] Hoffman, R.L., Kania, R.S., Brothers, M.A., Davies, J.F., Ferre, R.A., Gajiwala, K.S., et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19. *Journal of Medicinal Chemistry.* 2020, 63, 12725-47.
- [256] Ahmad, B., Batool, M., Ain, Q.U., Kim, M.S., Choi, S. Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations. *Int J Mol Sci.* 2021, 22, 9124.
- [257] Kirby, P., Dunne, A., King, D.H., Corey, L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. *The American Journal of Medicine.* 1990, 88, 465-9.
- [258] Luban, J., Sattler, R.A., Mühlberger, E., Graci, J.D., Cao, L., Weetall, M., et al. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. *Virus Res.* 2021, 292, 198246-.
- [259] Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. *Nature.* 2020, 582, 289-93.
- [260] Beigel, J.H., Tomashek, K.M., Dodd, L.E., Mehta, A.K., Zingman, B.S., Kalil, A.C., et al. Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine.* 2020, 383, 1813-26.
- [261] Tong, S., Su, Y., Yu, Y., Wu, C., Chen, J., Wang, S., et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. *Int J Antimicrob Agents.* 2020, 56, 106114-.
- [262] Xiong, R., Zhang, L., Li, S., Sun, Y., Ding, M., Wang, Y., et al. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2. *Protein Cell.* 2020, 11, 723-39.
- [263] Kashyap, T., Murray, J., Walker, C.J., Chang, H., Tamir, S., Hou, B., et al. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. *Antiviral Res.* 2021, 192, 105115-.
- [264] Lo, H.S., Hui, K.P.Y., Lai, H.-M., He, X., Khan, K.S., Kaur, S., et al. Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir. *ACS Central Science.* 2021, 7, 792-802.
- [265] Krafcikova, P., Silhan, J., Nencka, R., Boura, E. Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin. *Nature Communications.* 2020, 11, 3717.
- [266] Yin, W., Luan, X., Li, Z., Zhou, Z., Wang, Q., Gao, M., et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. *Nature Structural & Molecular Biology.* 2021, 28, 319-25.
- [267] Han, Y., Zeng, A., Liao, H., Liu, Y., Chen, Y., Ding, H. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. *International Immunopharmacology.* 2017, 42, 168-75.
- [268] Yang, L., Pei, R.-j., Li, H., Ma, X.-n., Zhou, Y., Zhu, F.-h., et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. *Acta Pharmacologica Sinica.* 2021, 42, 1347-53.

- [269] Wu, X., Yu, K., Wang, Y., Xu, W., Ma, H., Hou, Y., et al. Efficacy and safety of Triazavirin therapy for Coronavirus Disease 2019: a pilot randomized controlled trial. *Engineering (Beijing)*. 2020, 6, 1185-91.
- [270] Rut, W., Lv, Z., Zmudzinski, M., Patchett, S., Nayak, D., Snipas Scott, J., et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. *Science Advances*. 6, eabd4596.
- [271] Kumar, S.U., Priya, N.M., Nithya, S.R., Kannan, P., Jain, N., Kumar, D.T., et al. A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. *3 Biotech*. 2021, 11, 198.
- [272] Shen, Z., Ratia, K., Cooper, L., Kong, D., Lee, H., Kwon, Y., et al. Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. *Journal of medicinal chemistry*. 2021, acs.jmedchem.1c01307.
- [273] El Bairi, K., Trapani, D., Petrillo, A., Le Page, C., Zbakh, H., Daniele, B., et al. Repurposing anticancer drugs for the management of COVID-19. *Eur J Cancer*. 2020, 141, 40-61.
- [274] Neupane, N.P., Karn, A.K., Mukeri, I.H., Pathak, P., Kumar, P., Singh, S., et al. Molecular dynamics analysis of phytochemicals from *Ageratina adenophora* against COVID-19 main protease (M(pro)) and human angiotensin-converting enzyme 2 (ACE2). *Biocatal Agric Biotechnol*. 2021, 32, 101924-.
- [275] Vivek-Ananth, R.P., Rana, A., Rajan, N., Biswal, H.S., Samal, A. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection. *Molecules*. 2020, 25, 3822.
- [276] Tahir Ul Qamar, M., Alqahtani, S.M., Alamri, M.A., Chen, L.-L. Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. *J Pharm Anal*. 2020, 10, 313-9.
- [277] Yang, C.M., Cheng, H.Y., Lin, T.C., Chiang, L.C., Lin, C.C. The in vitro activity of geraniin and 1,3,4,6-tetra-O-galloyl-beta-D-glucose isolated from *Phyllanthus urinaria* against herpes simplex virus type 1 and type 2 infection. *J Ethnopharmacol*. 2007, 110, 555-8.
- [278] Bahadur Gurung, A., Ajmal Ali, M., Lee, J., Abul Farah, M., Mashay Al-Anazi, K. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. *J King Saud Univ Sci*. 2020, 32, 2845-53.
- [279] Majumder, R., Mandal, M. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an in silico docking and molecular dynamics simulation approach. *J Biomol Struct Dyn*. 2020, 1-16.
- [280] Swargiary, A., Mahmud, S., Saleh, M.A. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: an in silico approach to combat COVID-19. *J Biomol Struct Dyn*. 2020, 1-15.
- [281] Sakurai, Y., Ngwe Tun, M.M., Kurosaki, Y., Sakura, T., Inaoka, D.K., Fujine, K., et al. 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro. *Biochem Biophys Res Commun*. 2021, 545, 203-7.
- [282] Vardhan, S., Sahoo, S.K. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. *Comput Biol Med*. 2020, 124, 103936-.
- [283] Teli, D.M., Shah, M.B., Chhabria, M.T. In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19. *Frontiers in molecular biosciences*. 2021, 7, 599079-.

- [284] Zhang, Z.-R., Zhang, Y.-N., Li, X.-D., Zhang, H.-Q., Xiao, S.-Q., Deng, F., et al. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. *Signal transduction and targeted therapy*. 2020, 5, 218-.
- [285] Khubber, S., Hashemifesharaki, R., Mohammadi, M., Gharibzahedi, S.M.T. Garlic (*Allium sativum* L.): a potential unique therapeutic food rich in organosulfur and flavonoid compounds to fight with COVID-19. *Nutrition Journal*. 2020, 19, 124.
- [286] Kar, P., Kumar, V., Vellingiri, B., Sen, A., Jaishee, N., Anandraj, A., et al. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. *J Biomol Struct Dyn*. 2020, 1-11.
- [287] Kothandan, R., Rajan, C.A.S.G., Arjun, J., Raj, R.R.M., Syed, S. Virtual screening of phytochemical compounds as potential inhibitors against SARS-CoV-2 infection. *Beni Suef Univ J Basic Appl Sci*. 2021, 10, 9-.
- [288] Srivastava, A., Siddiqui, S., Ahmad, R., Mehrotra, S., Ahmad, B., Srivastava, A.N. Exploring nature's bounty: identification of *Withania somnifera* as a promising source of therapeutic agents against COVID-19 by virtual screening and in silico evaluation. *J Biomol Struct Dyn*. 2020, 1-51.
- [289] Rajagopal, K., Varakumar, P., Baliwada, A., Byran, G. Activity of phytochemical constituents of *Curcuma longa* (turmeric) and *Andrographis paniculata* against coronavirus (COVID-19): an in silico approach. *Futur J Pharm Sci*. 2020, 6, 104-.
- [290] Basu, A., Sarkar, A., Maulik, U. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2. *Scientific reports*. 2020, 10, 17699-.
- [291] Beheshtirouy, S., Khani, E., Khiali, S., Entezari-Maleki, T. Investigational antiviral drugs for the treatment of COVID-19 patients. *Archives of Virology*. 2022, 167, 751-805.
- [292] Khalil, A., Tazeddinova, D. The upshot of Polyphenolic compounds on immunity amid COVID-19 pandemic and other emerging communicable diseases: An appraisal. *Nat Prod Bioprospect*. 2020, 10, 411-29.
- [293] Hayashi, K., Narutaki, K., Nagaoka, Y., Hayashi, T., Uesato, S. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. *Biological & pharmaceutical bulletin*. 2010, 33, 1199-205.
- [294] Falade, V.A., Adelusi, T.I., Adedotun, I.O., Abdul-Hammed, M., Lawal, T.A., Agboluaje, S.A. In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M(pro)). *In Silico Pharmacol*. 2021, 9, 9-.
- [295] Huang, S., Liu, Y.e., Zhang, Y., Zhang, R., Zhu, C., Fan, L., et al. Baicalein inhibits SARS-CoV-2/VSV replication with interfering mitochondrial oxidative phosphorylation in a mPTP dependent manner. *Signal Transduction and Targeted Therapy*. 2020, 5, 266.
- [296] Chowdhury, P. In silico investigation of phytoconstituents from Indian medicinal herb '*Tinospora cordifolia* (giloy)' against SARS-CoV-2 (COVID-19) by molecular dynamics approach. *J Biomol Struct Dyn*. 2021, 39, 6792-809.
- [297] Beeraka, N.M., Sadhu, S.P., Madhunapantula, S.V., Rao Pragada, R., Svistunov, A.A., Nikolenko, V.N., et al. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status. *Frontiers in Immunology*. 2020, 11.
- [298] Nugraha, R.V., Ridwansyah, H., Ghozali, M., Khairani, A.F., Atik, N. Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. *Evid Based Complement Alternat Med*. 2020, 2020, 2560645-.
- [299] Yepes-Pérez, A.F., Herrera-Calderon, O., Sánchez-Aparicio, J.-E., Tiessler-Sala, L., Maréchal, J.-D., Cardona-G, W. Investigating Potential Inhibitory Effect of *Uncaria tomentosa* (Cat's Claw) against the Main Protease 3CL(pro) of SARS-CoV-2 by Molecular Modeling. *Evid Based Complement Alternat Med*. 2020, 2020, 4932572-.

- [300] Berretta, A.A., Silveira, M.A.D., C ndor Capcha, J.M., De Jong, D. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19. *Biomedicine & Pharmacotherapy*. 2020, 131, 110622.
- [301] Das, P., Majumder, R., Mandal, M., Basak, P. In-Silico approach for identification of effective and stable inhibitors for COVID-19 main protease (Mpro) from flavonoid based phytochemical constituents of *Calendula officinalis*. *Journal of Biomolecular Structure and Dynamics*. 2021, 39, 6265-80.
- [302] Belhassan, A., Zaki, H., Chtita, S., Alaqrbeh, M., Alsakhen, N., Benlyas, M., et al. Camphor, Artemisinin and Sumac Phytochemicals as inhibitors against COVID-19: Computational approach. *Comput Biol Med*. 2021, 136, 104758-.
- [303] Anil, S.M., Shalev, N., Vinayaka, A.C., Nadarajan, S., Namdar, D., Belausov, E., et al. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. *Scientific Reports*. 2021, 11, 1462.
- [304] Kumar, A., Choudhir, G., Shukla, S.K., Sharma, M., Tyagi, P., Bhushan, A., et al. Identification of phytochemical inhibitors against main protease of COVID-19 using molecular modeling approaches. *J Biomol Struct Dyn*. 2021, 39, 3760-70.
- [305] Vilhelmova, N., Jacquet, R., Quideau, S., Stoyanova, A., Galabov, A.S. Three-dimensional analysis of combination effect of ellagitannins and acyclovir on herpes simplex virus types 1 and 2. *Antiviral Res*. 2011, 89, 174-81.
- [306] Gurung, A.B., Ali, M.A., Lee, J., Farah, M.A., Al-Anazi, K.M. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach. *Life Sci*. 2020, 255, 117831-.
- [307] Du, R., Cooper, L., Chen, Z., Lee, H., Rong, L., Cui, Q. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro). *Antiviral Res*. 2021, 190, 105075-.
- [308] Argano, C., Mallaci Bocchio, R., Natoli, G., Scibetta, S., Lo Monaco, M., Corrao, S. Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis. *Pharmaceuticals (Basel)*. 2023, 16.
- [309] Yang, Z., Wang, Y., Zheng, Z., Zhao, S., Zhao, J., Lin, Q., et al. Antiviral activity of *Isatis indigotica* root-derived clemastanin B against human and avian influenza A and B viruses in vitro. *Int J Mol Med*. 2013, 31, 867-73.
- [310] Reyes, A.Z., Hu, K.A., Teperman, J., Wampler Muskardin, T.L., Tardif, J.-C., Shah, B., et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. *Annals of the Rheumatic Diseases*. 2021, 80, 550.
- [311] Manne, M., Goudar, G., Varikasuvu, S.R., Khetagoudar, M.C., Kanipakam, H., Natarajan, P., et al. Cordifolioside: potent inhibitor against M(pro) of SARS-CoV-2 and immunomodulatory through human TGF- β and TNF- α . *3 Biotech*. 2021, 11, 136-.
- [312] Binette, V., C t , S., Haddad, M., Nguyen, P.T., B langer, S., Bourgault, S., et al. Corilagin and 1,3,6-Tri-O-galloy- β -D-glucose: potential inhibitors of SARS-CoV-2 variants. *Physical chemistry chemical physics : PCCP*. 2021, 23, 14873-88.
- [313] Kordzadeh, A., Ramazani Saadatabadi, A., Hadi, A. Investigation on penetration of saffron components through lipid bilayer bound to spike protein of SARS-CoV-2 using steered molecular dynamics simulation. *Heliyon*. 2020, 6, e05681-e.
- [314] Miryan, M., Bagherniya, M., Sahebkar, A., Soleimani, D., Rouhani, M.H., Iraj, B., et al. Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory factors in patients with COVID-19: a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020, 21, 1027.

- [315] Pitsillou, E., Liang, J., Karagiannis, C., Ververis, K., Darmawan, K.K., Ng, K., et al. Interaction of small molecules with the SARS-CoV-2 main protease in silico and in vitro validation of potential lead compounds using an enzyme-linked immunosorbent assay. *Comput Biol Chem.* 2020, 89, 107408-.
- [316] Szabó, Z., Marosvölgyi, T., Szabó, É., Bai, P., Figler, M., Verzár, Z. The Potential Beneficial Effect of EPA and DHA Supplementation Managing Cytokine Storm in Coronavirus Disease. *Frontiers in Physiology.* 2020, 11.
- [317] Wang, A., Sun, Y., Liu, Q., Wu, H., Liu, J., He, J., et al. Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences. *Molecular biomedicine.* 2020, 1, 14.
- [318] Sharma, P., Joshi, T., Mathpal, S., Joshi, T., Pundir, H., Chandra, S., et al. Identification of natural inhibitors against Mpro of SARS-CoV-2 by molecular docking, molecular dynamics simulation, and MM/PBSA methods. *J Biomol Struct Dyn.* 2020, 1-12.
- [319] Verdoorn, B.P., Evans, T.K., Hanson, G.J., Zhu, Y., Langhi Prata, L.G.P., Pignolo, R.J., et al. Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. *Journal of the American Geriatrics Society.* 2021, 69, 3023-33.
- [320] Petit, L., Vernès, L., Cadoret, J.-P. Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2. *J Appl Phycol.* 2021, 1-24.
- [321] Kar, P., Sharma, N.R., Singh, B., Sen, A., Roy, A. Natural compounds from *Clerodendrum* spp. as possible therapeutic candidates against SARS-CoV-2: An in silico investigation. *J Biomol Struct Dyn.* 2021, 39, 4774-85.
- [322] Kim, Y.S., Chung, H.-S., Noh, S.G., Lee, B., Chung, H.Y., Choi, J.-G. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor. *Int J Mol Sci.* 2021, 22, 8604.
- [323] Islam, R., Parves, M.R., Paul, A.S., Uddin, N., Rahman, M.S., Mamun, A.A., et al. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2. *J Biomol Struct Dyn.* 2021, 39, 3213-24.
- [324] Singh, R., Gautam, A., Chandel, S., Ghosh, A., Dey, D., Roy, S., et al. Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study. *Molecules.* 2020, 25, 4604.
- [325] Haggag, Y.A., El-Ashmawy, N.E., Okasha, K.M. Is hesperidin essential for prophylaxis and treatment of COVID-19 Infection? *Med Hypotheses.* 2020, 144, 109957-.
- [326] Choy, K.-T., Wong, A.Y.-L., Kaewpreedee, P., Sia, S.F., Chen, D., Hui, K.P.Y., et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Res.* 2020, 178, 104786-.
- [327] Chikhale, R.V., Gupta, V.K., Eldesoky, G.E., Wabaidur, S.M., Patil, S.A., Islam, M.A. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies. *Journal of Biomolecular Structure and Dynamics.* 2021, 39, 6660-75.
- [328] Shadrack, D.M., Deogratias, G., Kiruri, L.W., Swai, H.S., Vianney, J.-M., Nyandoro, S.S. Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms. *J Mol Graph Model.* 2021, 105, 107871-.
- [329] Shree, P., Mishra, P., Selvaraj, C., Singh, S.K., Chaube, R., Garg, N., et al. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants - *Withania somnifera* (Ashwagandha), *Tinospora cordifolia* (Giloy) and *Ocimum sanctum* (Tulsi) - a molecular docking study. *J Biomol Struct Dyn.* 2020, 1-14.
- [330] Padhi, S., Masi, M., Chourasia, R., Rajashekar, Y., Rai, A.K., Evidente, A. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1

glycoprotein receptor binding domain and main protease inhibitors. *Eur J Pharmacol.* 2021, 890, 173648-.

[331] Arokiyaraj, S., Stalin, A., Kannan, B.S., Shin, H. Geranii Herba as a Potential Inhibitor of SARS-CoV-2 Main 3CL(pro), Spike RBD, and Regulation of Unfolded Protein Response: An In Silico Approach. *Antibiotics (Basel).* 2020, 9, 863.

[332] Yang, M.W., Chen, F., Zhu, D.J., Li, J.Z., Zhu, J.L., Zeng, W., et al. [Clinical efficacy of Matrine and Sodium Chloride Injection in treatment of 40 cases of COVID-19]. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica.* 2020, 45, 2221-31.

[333] Miller, R., Wentzel, A.R., Richards, G.A. COVID-19: NAD(+) deficiency may predispose the aged, obese and type2 diabetics to mortality through its effect on SIRT1 activity. *Med Hypotheses.* 2020, 144, 110044-.

[334] Balkrishna, A., Mittal, R., Arya, V. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19. *Current Pharmaceutical Biotechnology.* 2021, 22, 1350-9.

[335] Liu, S., Wei, W., Shi, K., Cao, X., Zhou, M., Liu, Z. In vitro and in vivo anti-hepatitis B virus activities of the lignan niranthin isolated from *Phyllanthus niruri* L. *Journal of Ethnopharmacology.* 2014, 155, 1061-7.

[336] Soto-Acosta, R., Bautista-Carbajal, P., Syed, G.H., Siddiqui, A., Del Angel, R.M. Nordihydroguaiaretic acid (NDGA) inhibits replication and viral morphogenesis of dengue virus. *Antiviral Res.* 2014, 109, 132-40.

[337] Wang, J., Zhang, X., Omarini, A.B., Li, B. Virtual screening for functional foods against the main protease of SARS-CoV-2. *Journal of Food Biochemistry.* 2020, 44, e13481.

[338] Verma, S., Twilley, D., Esmear, T., Oosthuizen, C.B., Reid, A.-M., Nel, M., et al. Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19). *Front Pharmacol.* 2020, 11.

[339] Zhong, B., Peng, W., Du, S., Chen, B., Feng, Y., Hu, X., et al. Oridonin Inhibits SARS-CoV-2 by Targeting Its 3C-Like Protease. *Small Sci.* 2022, 2, 2100124.

[340] Zálešák, F., Bon, D.J.-Y.D., Pospíšil, J. Lignans and Neolignans: Plant secondary metabolites as a reservoir of biologically active substances. *Pharmacological research.* 2019, 146, 104284.

[341] Yalçın, S., Yalçınkaya, S., Ercan, F. Determination of Potential Drug Candidate Molecules of the *Hypericum perforatum* for COVID-19 Treatment. *Curr Pharmacol Rep.* 2021, 1-7.

[342] Lani, R., Hassandarvish, P., Shu, M.-H., Phoon, W.H., Chu, J.J.H., Higgs, S., et al. Antiviral activity of selected flavonoids against Chikungunya virus. *Antiviral Res.* 2016, 133, 50-61.

[343] Singh, S., Sk, M.F., Sonawane, A., Kar, P., Sadhukhan, S. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis. *J Biomol Struct Dyn.* 2021, 39, 6249-64.

[344] Saeedi-Boroujeni, A., Mahmoudian-Sani, M.-R. Anti-inflammatory potential of Quercetin in COVID-19 treatment. *Journal of Inflammation.* 2021, 18, 3.

[345] Bosch-Barrera, J., Martin-Castillo, B., Buxó, M., Brunet, J., Encinar, J.A., Menendez, J.A. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. *J Clin Med.* 2020, 9, 1770.

[346] Gasparello, J., D'Aversa, E., Papi, C., Gambari, L., Grigolo, B., Borgatti, M., et al. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein. *Phytomedicine.* 2021, 87, 153583-.

- [347] Wang, S.-C., Chen, Y., Wang, Y.-C., Wang, W.-J., Yang, C.-S., Tsai, C.-L., et al. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease. *Am J Cancer Res.* 2020, 10, 4538-46.
- [348] Pollara, J.J., Laster, S.M., Petty, I.T.D. Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid. *Antiviral Res.* 2010, 88, 287-95.
- [349] Ray, M., Sarkar, S., Rath, S.N. Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2. *Genomics Inform.* 2020, 18, e43-e.
- [350] Ahmad, A., Rehman, M.U., Ahmad, P., Alkharfy, K.M. Covid-19 and thymoquinone: Connecting the dots. *Phytother Res.* 2020, 34, 2786-9.
- [351] Jovic, T.H., Ali, S.R., Ibrahim, N., Jessop, Z.M., Tarassoli, S.P., Dobbs, T.D., et al. Could Vitamins Help in the Fight Against COVID-19? *Nutrients.* 2020, 12, 2550.
- [352] Holford, P., Carr, A.C., Jovic, T.H., Ali, S.R., Whitaker, I.S., Marik, P.E., et al. Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. *Nutrients.* 2020, 12, 3760.
- [353] Straughn, A.R., Kakar, S.S. Withaferin A: a potential therapeutic agent against COVID-19 infection. *Journal of Ovarian Research.* 2020, 13, 79.
- [354] Kumar, V., Dhanjal, J.K., Bhargava, P., Kaul, A., Wang, J., Zhang, H., et al. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. *J Biomol Struct Dyn.* 2020, 1-13.
- [355] Kuo, Y.-C., Kuo, Y.-H., Lin, Y.-L., Tsai, W.-J. Yatein from *Chamaecyparis obtusa* suppresses herpes simplex virus type 1 replication in HeLa cells by interruption the immediate-early gene expression. *Antiviral Res.* 2006, 70, 112-20.